US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
EP2338333B1
(en)
|
2003-04-09 |
2017-09-06 |
ratiopharm GmbH |
Glycopegylation methods and proteins/peptides produced by the methods
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
US7855274B2
(en)
*
|
2003-12-03 |
2010-12-21 |
University Of Rochester |
Recombinant factor VIII having increased specific activity
|
US8361961B2
(en)
|
2004-01-08 |
2013-01-29 |
Biogenerix Ag |
O-linked glycosylation of peptides
|
EP1771066A2
(en)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
|
SI2586456T1
(en)
|
2004-10-29 |
2016-05-31 |
Ratiopharm Gmbh |
Remodeling and glycopegylation of fibroblast growth factor (FGF)
|
AU2006203792B2
(en)
|
2005-01-10 |
2011-11-03 |
Ratiopharm Gmbh |
Glycopegylated Granulocyte Colony Stimulating Factor
|
WO2006121569A2
(en)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
CA2604299A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation factor viii with enhanced stability and its derivates
|
EP2975135A1
(en)
|
2005-05-25 |
2016-01-20 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
WO2007065691A2
(en)
|
2005-12-07 |
2007-06-14 |
Technische Universität München |
Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
|
US20090203077A1
(en)
*
|
2006-06-30 |
2009-08-13 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
CA2656558A1
(en)
*
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
JP2009544327A
(en)
|
2006-07-21 |
2009-12-17 |
ノヴォ ノルディスク アー/エス |
Glycosylation of peptides with O-linked glycosylation sequences
|
US20100075375A1
(en)
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
LT2126106T
(en)
|
2007-02-23 |
2018-01-10 |
Sk Chemicals Co., Ltd. |
Process for producing and purifying factor viii and its derivatives
|
EP2144923B1
(en)
|
2007-04-03 |
2013-02-13 |
BioGeneriX AG |
Methods of treatment using glycopegylated g-csf
|
US9493499B2
(en)
|
2007-06-12 |
2016-11-15 |
Novo Nordisk A/S |
Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
|
US8183345B2
(en)
*
|
2007-11-01 |
2012-05-22 |
University Of Rochester |
Recombinant factor VIII having reduced inactivation by activated protein C
|
JP5647899B2
(en)
*
|
2008-01-08 |
2015-01-07 |
ラツィオファルム ゲーエムベーハーratiopharm GmbH |
Glycoconjugation of polypeptides using oligosaccharyltransferase
|
WO2009108806A1
(en)
|
2008-02-27 |
2009-09-03 |
Novo Nordisk A/S |
Conjugated factor viii molecules
|
CN102112144A
(en)
*
|
2008-05-16 |
2011-06-29 |
拜耳医药保健有限公司 |
Targeted coagulation factors and method of using the same
|
DK3178835T3
(en)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS INCLUDING THE SAME
|
US20110046060A1
(en)
|
2009-08-24 |
2011-02-24 |
Amunix Operating, Inc., |
Coagulation factor IX compositions and methods of making and using same
|
DK2482841T4
(en)
|
2009-10-02 |
2022-10-24 |
Childrens Hospital Philadelphia |
COMPOSITIONS AND METHODS FOR IMPROVING COAGULATION FACTOR VIII FUNCTION
|
JP5903048B2
(en)
|
2009-12-06 |
2016-04-13 |
バイオジェン ヘモフィリア インコーポレイテッド |
Factor VIII-Fc chimeric and hybrid polypeptides and methods of use thereof
|
EP2591101B1
(en)
|
2010-07-09 |
2018-11-07 |
Bioverativ Therapeutics Inc. |
Systems for factor viii processing and methods thereof
|
SG186875A1
(en)
|
2010-07-09 |
2013-02-28 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
BR112013011041B1
(en)
*
|
2010-11-05 |
2021-05-25 |
Baxalta GmbH |
factor viii variant, method for producing a fviii variant, use of factor viii variant, and, pharmaceutical composition
|
EP3527218A1
(en)
|
2011-06-10 |
2019-08-21 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
PT3513804T
(en)
|
2011-07-08 |
2022-06-02 |
Bioverativ Therapeutics Inc |
Factor viii chimeric and hybrid polypeptides, and methods of use thereof
|
US10656167B2
(en)
|
2011-07-25 |
2020-05-19 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
AU2012318292B2
(en)
|
2011-10-18 |
2015-08-20 |
Csl Limited |
Method for improving the stability of purified Factor VIII after reconstitution
|
KR20140083036A
(en)
|
2011-10-18 |
2014-07-03 |
체에스엘 베링 게엠베하 |
Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
|
ES2595160T3
(en)
|
2011-10-18 |
2016-12-28 |
Csl Behring Gmbh |
Combined use of a sulfated glucosaminoglycan and a hyaluronidase to improve the bioavailability of Factor VIII
|
CA2863329C
(en)
|
2012-01-12 |
2023-01-03 |
Biogen Idec Ma Inc. |
Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
|
PL2804623T3
(en)
|
2012-01-12 |
2020-03-31 |
Bioverativ Therapeutics Inc. |
Chimeric factor viii polypeptides and uses thereof
|
AU2013204636B2
(en)
|
2012-02-15 |
2016-04-14 |
Bioverativ Therapeutics Inc. |
Recombinant Factor VIII proteins
|
BR112014020694A2
(en)
|
2012-02-15 |
2018-05-08 |
Amunix Operating Inc. |
factor viii fusion protein comprising extended recombinant polypeptide (xten) fusion factor polypeptide and its method of manufacture, nucleic acid, vectors, host cell, as well as pharmaceutical composition and its use in the treatment of coagulopathy, bleeding episode and hemophilia a
|
CN104519897A
(en)
|
2012-06-08 |
2015-04-15 |
比奥根艾迪克Ma公司 |
Procoagulant compounds
|
CN104427995A
(en)
|
2012-06-08 |
2015-03-18 |
比奥根艾迪克Ma公司 |
Chimeric clotting factors
|
EP3404105A1
(en)
|
2012-07-06 |
2018-11-21 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
KR101395736B1
(en)
*
|
2012-07-10 |
2014-05-16 |
아주대학교산학협력단 |
Human coagulation factor Ⅷdomain specific antibody and method for producing thereof
|
EA029685B1
(en)
|
2012-07-11 |
2018-04-30 |
Амуникс Оперэйтинг Инк. |
Factor viii complex with xten and von willebrand factor protein, and uses thereof (embodiments)
|
EP2877202A4
(en)
|
2012-07-25 |
2016-06-01 |
Biogen Ma Inc |
Blood factor monitoring assay and uses thereof
|
AU2013331000B2
(en)
|
2012-10-18 |
2018-04-19 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
EP3943102A1
(en)
|
2012-10-30 |
2022-01-26 |
Bioverativ Therapeutics Inc. |
Methods of using fviii polypeptide
|
HUE063051T2
(en)
|
2013-02-15 |
2023-12-28 |
Bioverativ Therapeutics Inc |
Optimized factor viii gene
|
SG10201707600XA
(en)
|
2013-03-15 |
2017-11-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
TWI629993B
(en)
|
2013-03-15 |
2018-07-21 |
美商生物化學醫療公司 |
Factor viii polypeptide formulations
|
ES2657291T3
(en)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
A covalent complex of von Willebrand factor and factor VIII associated by a disulfide bridge
|
JP2016523919A
(en)
|
2013-06-28 |
2016-08-12 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Thrombin cleavable linker having XTEN and use thereof
|
EP3875106A1
(en)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Purification of chimeric fviii molecules
|
TWI667255B
(en)
|
2013-08-14 |
2019-08-01 |
美商生物化學醫療公司 |
Factor viii-xten fusions and uses thereof
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
EP4332839A3
(en)
|
2013-12-06 |
2024-06-05 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
RS63583B1
(en)
|
2014-01-10 |
2022-10-31 |
Bioverativ Therapeutics Inc |
Factor viii chimeric proteins and uses thereof
|
RU2695428C2
(en)
*
|
2014-01-20 |
2019-07-23 |
Октафарма Аг |
Method of producing factor viii, having improved ratio fviii:c/fviii:ag
|
AU2015214245B2
(en)
|
2014-02-04 |
2020-09-10 |
Biogen Ma Inc. |
Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
|
CA2956412A1
(en)
|
2014-08-04 |
2016-02-11 |
Csl Limited |
Factor viii formulation
|
MA40864A
(en)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
|
US11155601B2
(en)
|
2015-03-06 |
2021-10-26 |
CSL Behring Lengnau AG |
Modified von Willebrand factor having improved half-life
|
SG11201708755WA
(en)
|
2015-05-22 |
2017-12-28 |
Csl Behring Recombinant Facility Ag |
Truncated von willebrand factor polypeptides for treating hemophilia
|
JP6651548B2
(en)
|
2015-05-22 |
2020-02-19 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
Method for producing a modified von Willebrand factor
|
TWI741992B
(en)
|
2015-08-03 |
2021-10-11 |
美商百歐維拉提夫治療公司 |
Factor ix fusion proteins and methods of making and using same
|
WO2017050820A1
(en)
*
|
2015-09-22 |
2017-03-30 |
Novo Nordisk A/S |
Fviii fusion proteins
|
EP3374388A1
(en)
|
2015-11-13 |
2018-09-19 |
Baxalta Incorporated |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
CN116479001A
(en)
|
2015-11-13 |
2023-07-25 |
武田药品工业株式会社 |
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia a
|
EP3400002B1
(en)
|
2016-01-07 |
2022-02-02 |
CSL Behring Lengnau AG |
Mutated truncated von willebrand factor
|
BR112018015659A2
(en)
|
2016-02-01 |
2018-12-26 |
Bioverativ Therapeutics Inc |
optimized factor viii genes
|
CN109790529A
(en)
|
2016-06-24 |
2019-05-21 |
财团法人牧岩生命科学研究所 |
Chimeric protein and application thereof comprising FVIII the and vWF factor
|
EP3476860A4
(en)
|
2016-06-24 |
2020-01-22 |
Mogam Institute for Biomedical Research |
Recombinant single-chain fviii and chemical conjugate thereof
|
JP6351679B2
(en)
*
|
2016-09-30 |
2018-07-04 |
エスケー ケミカルズ カンパニー リミテッド |
Method for producing and purifying factor VIII and its derivatives
|
SG11201903950UA
(en)
|
2016-11-11 |
2019-05-30 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
AU2017358865A1
(en)
|
2016-11-11 |
2019-05-09 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
|
US20190381149A1
(en)
|
2016-12-02 |
2019-12-19 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
AU2017368328A1
(en)
|
2016-12-02 |
2019-07-18 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
DK3641800T3
(en)
|
2017-06-22 |
2024-01-02 |
CSL Behring Lengnau AG |
MODULATION OF FVIII IMMUNOGENICITY BY TRUNCATED VWF
|
AU2018313921A1
(en)
|
2017-08-09 |
2020-03-12 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof
|
JP7110360B2
(en)
|
2017-10-09 |
2022-08-01 |
テルモ ビーシーティー バイオテクノロジーズ,エルエルシー |
Freeze-drying method
|
MX2020008152A
(en)
|
2018-02-01 |
2020-11-24 |
Bioverativ Therapeutics Inc |
Use of lentiviral vectors expressing factor viii.
|
RU2020136050A
(en)
|
2018-04-04 |
2022-05-06 |
Сайджилон Терапьютикс, Инк. |
IMPLANTABLE PARTICLES AND CORRESPONDING METHODS
|
MX2020012397A
(en)
|
2018-05-18 |
2021-04-12 |
Bioverativ Therapeutics Inc |
Methods of treating hemophilia a.
|
TW202006141A
(en)
|
2018-07-16 |
2020-02-01 |
美商巴克斯歐塔公司 |
Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression
|
WO2020033863A1
(en)
|
2018-08-09 |
2020-02-13 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
US20220118063A1
(en)
*
|
2018-09-19 |
2022-04-21 |
Cell Machines, Inc. |
Methods and compositions related to improved factor viii long half-life coagulation complexes
|
UY38389A
(en)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
|
IL284648B1
(en)
|
2019-01-16 |
2024-08-01 |
Baxalta Incorporated |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
MA54951A
(en)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
GENE EDITING FOR HEMOPHILIA A WITH ENHANCED FACTOR VIII EXPRESSION
|
US11604026B2
(en)
|
2019-03-14 |
2023-03-14 |
Terumo Bct Biotechnologies, Llc |
Lyophilization loading tray assembly and system
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
US20220233650A1
(en)
|
2019-06-19 |
2022-07-28 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii-fc for treating hemophilia and low bone mineral density
|
WO2021001522A1
(en)
|
2019-07-04 |
2021-01-07 |
CSL Behring Lengnau AG |
A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
|
EP4058049A1
(en)
|
2019-11-11 |
2022-09-21 |
CSL Behring Lengnau AG |
Polypeptides for inducing tolerance to factor viii
|
WO2021119357A2
(en)
|
2019-12-12 |
2021-06-17 |
Baxalta Incorporated |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
JP2021156833A
(en)
*
|
2020-03-30 |
2021-10-07 |
シスメックス株式会社 |
Measuring method of blood coagulation activity
|
EP4355768A1
(en)
|
2021-06-14 |
2024-04-24 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
AR126846A1
(en)
|
2021-08-23 |
2023-11-22 |
Bioverativ Therapeutics Inc |
OPTIMIZED FACTOR VIII GENES
|
CN118019758A
(en)
|
2021-09-30 |
2024-05-10 |
比奥维拉迪维治疗股份有限公司 |
Nucleic acids encoding reduced immunogenicity factor VIII polypeptides
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|